Prelude Therapeutics INC

Prelude Therapeutics announced its second quarter 2026 financial results, highlighting progress in its oncology pipeline and a cash runway extending into Q2 2028.

Prelude Therapeutics Incorporated announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Prelude Therapeutics reported Q1 2026 financial results, highlighting progress in its PRT12396 and PRT13722 programs, and extended cash runway into Q2 2028.

Prelude Therapeutics announced new preclinical data for its lead candidate, PRT13722, a selective KAT6A degrader, showing potential for differentiated efficacy and safety in HR+/HER2- breast cancer.

Prelude Therapeutics Incorporated announced the appointment of Dr. Charles Morris as its new Chief Medical Officer, effective April 20, 2026, bringing extensive oncology drug development experience to the company.

Prelude Therapeutics Inc. has filed a prospectus supplement to offer and sell up to an additional $25.0 million of its common stock through an at-the-market facility.

Prelude Therapeutics Incorporated announced its financial results for the second quarter ended June 30, 2026, highlighting progress in its oncology pipeline and a significant capital raise.

Prelude Therapeutics Inc. reported its first-quarter 2026 financial results, highlighting progress in its oncology pipeline and a significant cash position following a recent offering.

Prelude Therapeutics reported a reduced net loss for Q3 2025, secured $60 million in new capital from Incyte, and strategically paused its SMARCA2 degrader program to focus on JAK2 and KAT6A, while acknowledging substantial doubt about its going concern ability.

Prelude Therapeutics reported continued operating losses and a going concern warning, alongside progress in its oncology pipeline and a Nasdaq minimum bid price deficiency.

Prelude Therapeutics reports a net loss of $32.1 million for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern without additional funding.

Prelude Therapeutics reported a net loss of $32.3 million for the third quarter of 2024, while highlighting progress in its clinical programs and a new licensing agreement.

Prelude Therapeutics advances its clinical-stage precision oncology pipeline, showcasing positive Phase 1 data for PRT3789 and initiating a Phase 2 trial, while strategically partnering to expand its ADC capabilities.

Prelude Therapeutics updates its registration rights agreement and files its annual 10-K report, detailing its financial status and clinical development pipeline.

Baker Bros. Advisors LP, a significant holder and director-affiliated entity, has acquired 38,000 non-qualified stock options for Prelude Therapeutics Inc. (PRLD) with a strike price of $3.94.

Director Katina Dorton was granted 38,000 stock options in Prelude Therapeutics Inc. as part of a standard equity compensation package.

Director Martin Babler was granted 38,000 stock options in Prelude Therapeutics Inc. as part of an equity compensation award.

Director David P. Bonita was granted 38,000 stock options in Prelude Therapeutics Inc. as part of a standard compensation arrangement.

Director Victor Sandor was granted 38,000 stock options in Prelude Therapeutics Inc. as part of an equity compensation award.

Paul A. Friedman, a Director at Prelude Therapeutics Inc., has acquired stock options granting the right to buy 38,000 shares.

Prelude Therapeutics Inc. has filed a definitive proxy statement with the SEC.

Prelude Therapeutics is asking stockholders to approve an amendment to its restated certificate of incorporation to increase the number of authorized non-voting common shares, providing greater flexibility for future business needs.

Prelude Therapeutics Incorporated files a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.

Prelude Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to elect directors and ratify the appointment of its independent accounting firm.

OrbiMed Advisors reports a change in beneficial ownership of Prelude Therapeutics following a recent public offering.

Baker Bros. Advisors reported an increased beneficial ownership of 15.5% in Prelude Therapeutics following a recent public offering.

Baker Bros. Advisors has filed an amendment to its Schedule 13D, confirming its 23.5% beneficial ownership in Prelude Therapeutics Inc. and announcing a change in its board representation with Dr. Paul C. Scherer joining and Julian C. Baker stepping down.

Soleus Capital Management L.P. and affiliated entities report beneficial ownership of 5.2% of Prelude Therapeutics Inc. common stock as of April 21, 2026.

RA Capital Management and associated parties have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Prelude Therapeutics Incorporated.

Krishna Vaddi, a key insider, has reported a beneficial ownership of 13.15% in Prelude Therapeutics Inc., totaling 6,745,647 shares.

Incyte Corporation has reported a 9.9% beneficial ownership stake in Prelude Therapeutics, Inc., primarily through convertible non-voting common stock.

Krishna Vaddi, a key individual associated with Prelude Therapeutics Inc., has filed an amended Schedule 13G, disclosing a beneficial ownership of 13.8% of the company's common stock as of March 31, 2025.

Krishna Vaddi, an individual, has reported a 9.5% beneficial ownership stake in Prelude Therapeutics Inc., totaling 5,489,130 shares as of December 31, 2024.